Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Just saw Dawg’s data tracker
View:
Post by CancerSlayer on Apr 06, 2022 5:06am

Just saw Dawg’s data tracker

Updated data interpretation noted....thanks.

Just noted what appears to be a minor error (transposed 180 day pending & total responders %s) in the optimized treatment table:

Study II Clinical Study Data (Optimized: Post August 1, 2020):

Assessment (Days)

Complete Response (“CR”)2

Partial Response (“PR”)3

Pending4

CR (Evaluable Patients)5

Total Responders (CR + PR)6

Potential Responders (CR + PR + Pending)7

90

52.2%

17.4%

13.0%

60.0%

69.6%

82.6%

180

22.2%

18.5%

40.7%

40.0%

42.3%

83.0%

270

14.8%

3.7%

59.3%

36.4%

18.5%

77.8%

360

3.7%

7.4%

66.7%

11.1%

11.1%

77.8%

450

3.7%

3.7%

66.7%

11.1%

7.4%

74.1%

 

I believe should read:

 

Study II Clinical Study Data (Optimized: Post August 1, 2020):

Assessment (Days)

Complete Response (“CR”)2

Partial Response (“PR”)3

Pending4

CR (Evaluable Patients)5

Total Responders (CR + PR)6

Potential Responders (CR + PR + Pending)7

90

52.2%

17.4%

13.0%

60.0%

69.6%

82.6%

180

22.2%

18.5%

42.3%

40.0%

40.7%

83.0%

270

14.8%

3.7%

59.3%

36.4%

18.5%

77.8%

360

3.7%

7.4%

66.7%

11.1%

11.1%

77.8%

450

3.7%

3.7%

66.7%

11.1%

7.4%

74.1%

Comment by Lesalpes29 on Apr 06, 2022 5:59am
Thank you Dr Dawg's to put results in a way I can understand them. Was not an easy Day yesterday but with many good People with knowledge I hold my shares and bought a few at .37 and .325. BTD soon is still a good possibility with the last results. Probably not soon enough for some apparently.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250